Alligator Bioscienes - Halvårsrapport 2019
-
Alligator Bioscience AB (publ) Interim report January-June 2019
"The results that Janssen presented at ASCO show that ADC-1013 can be administered in considerably higher doses than any of the other CD40 antibodies in clinical development. The study also shows early signs of clinical efficacy", CEO Per Norlén comments.
https://lnkd.in/g-PW2df #immunooncology
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind